What is Vect-Horus?
Vect-Horus operates at the intersection of biotechnology and advanced pharmacology, specializing in the development of innovative targeting technology designed to enhance the systemic delivery of therapeutic and imaging agents. The company's core competency lies in its proprietary platform, which facilitates the transport of RNA-targeted medicines across the blood-brain barrier, addressing critical unmet needs in neurological disease treatment. By optimizing the precision of drug delivery to specific organs and tumors, Vect-Horus has positioned itself as a high-value partner for global pharmaceutical entities. Their market position is defined by a dual-track strategy: advancing an internal pipeline of CNS-focused therapeutics while simultaneously leveraging collaborative research agreements to validate their delivery technology across diverse therapeutic modalities.
How much funding has Vect-Horus raised?
Vect-Horus has raised a total of $31.4M across 5 funding rounds:
Angel/Seed
$1.8M
Series A
$3M
Series B
$4.2M
Series C
$7.9M
Series D
$14.5M
Angel/Seed (2014): $1.8M, investors not publicly disclosed
Series A (2017): $3M, investors not publicly disclosed
Series B (2018): $4.2M supported by Financiere Tuileries Co-Invest, CAAP Creation, and SCR Provencale et Corse
Series C (2020): $7.9M, investors not publicly disclosed
Series D (2021): $14.5M, investors not publicly disclosed
Key Investors in Vect-Horus
Financiere Tuileries Co-Invest
A specialized investment firm focused on providing growth capital to innovative companies within the European technology and life sciences sectors.
CAAP Creation
A venture capital entity dedicated to supporting early-to-growth stage enterprises with a focus on technological innovation and regional economic development.
SCR Provencale et Corse
A regional private equity firm that provides strategic financing and operational support to high-potential businesses in the French market.
What's next for Vect-Horus?
With the recent influx of capital, Vect-Horus is well-positioned to scale its operational capacity and deepen its research into RNA-based delivery mechanisms. The strategic roadmap likely involves expanding clinical trial footprints and strengthening intellectual property portfolios to maintain a competitive edge in the CNS therapeutic market. As the company moves forward, the focus will shift toward commercializing its delivery platform through high-value licensing agreements and potential co-development partnerships. Investors and industry stakeholders will be monitoring the firm's ability to translate its technological breakthroughs into tangible clinical outcomes, which will be essential for sustaining long-term growth and achieving future liquidity events in the competitive biotech landscape.
See full Vect-Horus company page
